PP2A optimization for neuronal resilience
PrimarySignum's EHT-related theory is that coffee-derived eicosanoyl-5-hydroxytryptamide, especially in combination with caffeine, supports brain aging and neurodegenerative disease resilience by optimizing PP2A, described as a master protein regulator important for maintaining strong neuronal connections. The causal claim is that improving PP2A activity should preserve synaptic integrity and thereby improve or maintain cognitive functions such as memory, focus, alertness, and resistance to age-associated cognitive decline. Testable predictions are that EHT-containing interventions should increase or normalize PP2A-related signaling, preserve synaptic markers or neuronal connectivity in aging or neurodegeneration models, and improve behavioral or functional endpoints in models of Parkinson's disease, dementia with Lewy bodies, or cognitive aging compared with controls.
Popperian evaluation
The premise is biologically credible at the broad level: PP2A regulates phosphorylation networks, and synaptic integrity is a plausible route into cognition. The weak point is causal sufficiency. The theory asks PP2A optimization to carry a large part of neuronal resilience, but the supplied evidence does not show that PP2A change alone preserves synapses or cognition across aging, Parkinson's disease, and dementia with Lewy bodies.
Supporting evidence: The theory names a concrete molecule, eicosanoyl-5-hydroxytryptamide, and a concrete mechanistic target, PP2A-related signaling.; The reasoning chain links PP2A activity to synaptic markers, neuronal connectivity, and behavioral endpoints, which are measurable biological levels rather than mood claims.; One listed publication reports neuroprotection by EHT plus caffeine in Parkinson's disease and dementia with Lewy bodies models.
Counter evidence: The evidence context relies mainly on one Signum-linked publication entry with no abstract, journal, or publication year supplied.; The key assumption, that improving PP2A activity is causally sufficient to preserve synaptic integrity, is stated rather than demonstrated here.; Generalizing disease-model neuroprotection to broad brain aging is marked low confidence in the provided reasoning nodes.
The theory can explain the reported model-level neuroprotection if EHT plus caffeine changes PP2A signaling and downstream synaptic resilience. But the same observations could also come from caffeine pharmacology, antioxidant effects, anti-inflammatory effects, model-specific artifacts, or unrelated actions of EHT. Without target-engagement data and rescue or blockade experiments, PP2A is a plausible explanation, not the winning explanation.
Supporting evidence: The model prediction is aligned with the reported observation: EHT-containing interventions are expected to improve functional endpoints in Parkinson's disease and dementia with Lewy bodies models.; The theory predicts a mechanistic sequence: PP2A signaling first, then synaptic preservation, then behavior.
Counter evidence: The supplied evidence does not show that PP2A modulation mediates the observed neuroprotection.; The combination with caffeine creates a confound unless EHT alone, caffeine alone, and the combination are compared across PP2A and behavioral endpoints.; The theory does not yet distinguish broad neuronal support from disease-model-specific benefit.
This is the strongest Popperian feature. The theory makes several concrete predictions that can fail: EHT-containing interventions should normalize PP2A-related signaling, preserve synaptic markers or connectivity, and improve functional outcomes against controls. A clean negative result across target engagement, synaptic readouts, and behavior would hit the theory directly.
Supporting evidence: The theory predicts PP2A-related signaling changes compared with controls.; It predicts preservation of synaptic markers or neuronal connectivity in aging or neurodegeneration models.; It predicts behavioral or functional improvement in Parkinson's disease, dementia with Lewy bodies, or cognitive aging models.
Counter evidence: The word "optimize" is loose unless the desired direction, assay, tissue, timing, and threshold for PP2A activity are specified.; Memory, focus, and alertness are broad endpoints, so human claims would need preregistered measures before they become sharp tests.; If failures are explained away as wrong dose, wrong caffeine ratio, or wrong disease model, the theory would lose falsifiability.
Reasoning tree
Public endorsements
Perez appears publicly tied to Signum and shared a 2017 Facebook post about co-founder Jeff Stock presenting EHT at a geriatrics conference. That is a public mention of the EHT program, but the evidence here does not show Perez explicitly endorsing the specific PP2A-neuronal-resilience theory, and it does not show a contradiction either.
Evidence publication IDs: ea093b91-db6d-4e85-978d-7e4a75ce0828
The public evidence ties Jeffry Stock to Signum and its EHT research, but it does not show a direct public statement from him personally endorsing the PP2A-neuronal resilience theory. He is identified as a co-founder of Signum Biosciences, and BioSignum publicly said it had a publication collaboration with him. That is stronger than silence, but weaker than a clear personal endorsement.
Jose Fernandez is listed as an inventor on Signum Biosciences' patent application WO2016061357A1 covering tryptamide compositions, including EHT-related methods of use. That is a public link to the underlying EHT program, but this record does not contain a direct public statement from him endorsing the specific PP2A and neuronal-resilience theory.
Evidence publication IDs: 7d51e666-65f9-4d4d-80e9-bd11858ed9d6
There is no direct quote from Masanori Tamura and no listed publication tied to him that mentions PP2A, EHT, caffeine, neuronal resilience, or the cognitive-aging theory. The provided records are company or brand coverage about Signum Biosciences and Epicutis, not public statements from Tamura on this mechanism.
Maxwell Stock is identified as Signum Biosciences' founder and CEO, and public videos present him as the person explaining the science behind Signum's EHT-linked products. A separate EHT publication states the exact PP2A-to-synaptic-health claim. We do not have a direct quote from Stock in this dossier, but the public promotional context points to endorsement rather than mere passing mention.